Leighton joined Brandon Capital in 2015.
Leighton is an American serial entrepreneur and venture investor. He was previously Managing Director of Interhealth Partners and Alloy Ventures.
Prior to joining Brandon Capital, Leighton founded, and served as Managing Director and President of , the Pharma Division at Affymax NV (acquired by Glaxo in 1995). He was the founding investor, Chairman and CEO of Aviron (acquired by MedImmune) and Avidia (acquired by Amgen).
Leighton completed internal medicine training at Duke and the Peter Bent Brigham Hospital, where he held appointments at the Harvard Medical School and School of Public Health.
He is currently Non-Executive Chairman of Global Kinetics, a director of Allay Therapeutics and Glyscend Therapeutics.
Leighton has a Bachelor of Science from Rice University and an MD from the University of Texas Health Science Center.